Literature DB >> 10476502

Minus-power intraocular lenses to correct refractive errors in myopic pseudophakia.

J P Gills1, R E Fenzl.   

Abstract

PURPOSE: To evaluate the effectiveness of a secondary, piggyback, minus-power intraocular lens (IOL) to correct the refractive error in patients with myopic pseudophakia.
METHODS: In this prospective noncomparative cohort study, 51 myopic pseudophakic patients received implantation of a minus-power IOL as a secondary procedure to correct residual pseudophakic myopia.
RESULTS: The mean residual myopia of -3.05 diopters (D) was reduced to -0.38 D. All eyes were within +/- 1.00 D of the desired refraction. Uncorrected visual acuity was 20/40 or better in 72% of eyes, and best corrected visual acuity was 20/40 or better in 96%. Uncorrected visual acuity improved by 2 or more lines in 85% of eyes and by 5 or more lines in 65%.
CONCLUSION: Clinical outcomes can now be improved in patients with myopic pseudophakia whose previous options (i.e., lens exchange or refractive surgery) were more traumatic or less predictable.

Entities:  

Mesh:

Year:  1999        PMID: 10476502     DOI: 10.1016/s0886-3350(99)00163-7

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  3 in total

1.  Secondary piggyback implantation versus IOL exchange for symptomatic pseudophakic residual ametropia.

Authors:  Hatem E El Awady; Asaad A Ghanem
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-16       Impact factor: 3.117

2.  Primary polypseudophakia for cataract surgery in hypermetropic eyes: refractive results and long term stability of the implants within the capsular bag.

Authors:  H Eleftheriadis; A Sciscio; A Ismail; C C Hull; C Liu
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

3.  [Refractive long-term results after piggyback intraocular lens implantation].

Authors:  B Moustafa; H Häberle; C Wirbelauer; D T Pham
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.